Literature DB >> 12663640

How morphometric analysis of metastatic load predicts the (un)usefulness of PET scanning: the case of lymph node staging in melanoma.

G S Mijnhout1, O S Hoekstra, A van Lingen, P J van Diest, H J Adèr, A A Lammertsma, R Pijpers, S Meijer, G J J Teule.   

Abstract

BACKGROUND: In primary cutaneous melanoma, the sentinel node (SN) biopsy is an accurate method for the staging of the lymph nodes. Positron emission tomography (PET) has been suggested as a useful alternative. However, the sensitivity of PET may be too low to detect SN metastases, which are often small. AIM: To predict the value of PET for initial lymph node staging in melanoma based on morphometric analysis of SN metastatic load, without exposing patients to PET.
MATERIALS AND METHODS: In 59 SN positive patients with melanoma, the sizes of tumour deposits in the SNs and subsequent dissection specimens were measured by morphometry and correlated with the detection limits of current and future PET scanners.
RESULTS: The median tumour volume within the basin was 0.15 mm(3) (range, 0.0001-118.86). Seventy per cent of these deposits were smaller than 1 mm(3). State of the art PET scanners that have a resolution of about 5 mm would detect only 15-49% of positive basins. Logistic regression analysis revealed no pretest indicators identifying patients expected to have a positive PET. However, the SN tumour load was a significant and single predictor of the presence of PET detectable residual tumour.
CONCLUSION: Morphometric analysis of metastatic load predicts that PET scanning is unable to detect most metastatic deposits in sentinel lymph nodes of patients with melanoma because the metastases are often small. Therefore, the SN biopsy remains the preferred method for initial regional staging.

Entities:  

Mesh:

Year:  2003        PMID: 12663640      PMCID: PMC1769919          DOI: 10.1136/jcp.56.4.283

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  29 in total

1.  Re: Axillary lymph node staging in breast cancer by 2-fluoro-2-deoxy-D-glucose-positron emission tomography: clinical evaluation and alternative management.

Authors:  H Torrenga; J Licht; J J van der Hoeven; O S Hoekstra; S Meijer; P J van Diest
Journal:  J Natl Cancer Inst       Date:  2001-11-07       Impact factor: 13.506

2.  Comparison of positron emission tomography scanning and sentinel node biopsy in the detection of micrometastases of primary cutaneous malignant melanoma.

Authors:  K M Acland; C Healy; E Calonje; M O'Doherty; T Nunan; C Page; E Higgins; R Russell-Jones
Journal:  J Clin Oncol       Date:  2001-05-15       Impact factor: 44.544

3.  Pattern and incidence of first site recurrences following sentinel node procedure in melanoma patients.

Authors:  Markwin G Statius Muller; Paul A M van Leeuwen; Paul J van Diest; Rik Pijpers; Robert J Nijveldt; Ronald J C L M Vuylsteke; Sybren Meijer
Journal:  World J Surg       Date:  2002-09-26       Impact factor: 3.352

4.  Axillary lymph node staging in breast cancer by 2-fluoro-2-deoxy-D-glucose-positron emission tomography: clinical evaluation and alternative management.

Authors:  M Greco; F Crippa; R Agresti; E Seregni; A Gerali; R Giovanazzi; A Micheli; S Asero; C Ferraris; M Gennaro; E Bombardieri; N Cascinelli
Journal:  J Natl Cancer Inst       Date:  2001-04-18       Impact factor: 13.506

5.  FDG-PET sensitivity for melanoma lymph node metastases is dependent on tumor volume.

Authors:  J D Wagner; D S Schauwecker; D Davidson; S Wenck; S H Jung; G Hutchins
Journal:  J Surg Oncol       Date:  2001-08       Impact factor: 3.454

6.  No indication for performing sentinel node biopsy in melanoma patients with a Breslow thickness of less than 0.9 mm.

Authors:  M G Statius Muller; P A van Leeuwen; P J van Diest; R J Vuylsteke; R Pijpers; S Meijer
Journal:  Melanoma Res       Date:  2001-06       Impact factor: 3.599

Review 7.  PET in oncology: will it replace the other modalities?

Authors:  C K Hoh; C Schiepers; M A Seltzer; S S Gambhir; D H Silverman; J Czernin; J Maddahi; M E Phelps
Journal:  Semin Nucl Med       Date:  1997-04       Impact factor: 4.446

8.  Initial assessment of positron emission tomography for detection of nonpalpable regional lymphatic metastases in melanoma.

Authors:  J D Wagner; D Schauwecker; G Hutchins; J J Coleman
Journal:  J Surg Oncol       Date:  1997-03       Impact factor: 3.454

9.  Initial assessment of positron emission tomography using 2-fluorine-18-fluoro-2-deoxy-D-glucose in the imaging of malignant melanoma.

Authors:  L S Gritters; I R Francis; K R Zasadny; R L Wahl
Journal:  J Nucl Med       Date:  1993-09       Impact factor: 10.057

Review 10.  Potential applications of positron emission tomography in surgical oncology.

Authors:  O E Nieweg
Journal:  Eur J Surg Oncol       Date:  1994-08       Impact factor: 4.424

View more
  4 in total

1.  Direct comparison of [18F]FDG PET/CT with PET alone and with side-by-side PET and CT in patients with malignant melanoma.

Authors:  Felix M Mottaghy; Cord Sunderkötter; Roland Schubert; Petra Wohlfart; Norbert M Blumstein; Bernd Neumaier; Gerhard Glatting; Cueneyt Ozdemir; Andreas K Buck; Karin Scharffetter-Kochanek; Sven N Reske
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-02-13       Impact factor: 9.236

Review 2.  A review of imaging agent development.

Authors:  Eric D Agdeppa; Mary E Spilker
Journal:  AAPS J       Date:  2009-05-05       Impact factor: 4.009

3.  Positron emission tomography using [18F]fluorodeoxyglucose (FDG-PET) in the clinically negative neck: is it likely to be superior?

Authors:  Jolijn Brouwer; Remco de Bree; Emile F I Comans; Jonas A Castelijns; Otto S Hoekstra; C René Leemans
Journal:  Eur Arch Otorhinolaryngol       Date:  2003-12-17       Impact factor: 2.503

4.  Preoperative FDG-PET/CT Is an Important Tool in the Management of Patients with Thick (T4) Melanoma.

Authors:  Rodrigo Arrangoiz; Pavlos Papavasiliou; Carrie A Stransky; Jian Q Yu; Li Tianyu; Elin R Sigurdson; Adam C Berger; Jeffrey M Farma
Journal:  Dermatol Res Pract       Date:  2012-05-13
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.